Trial Profile
A pilot double-blind parallel-group placebo controlled randomised trial of the effect of preoperative ferric carboxymaltose infusion on total haemoglobin mass and exercise capacity in patients with non-anaemic iron deficiency undergoing major surgery for colorectal cancer.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms ADEPT
- 09 Aug 2021 Status changed from recruiting to discontinued due to participant recruitment difficulties.
- 04 Sep 2018 New trial record